5 Results for "

primary hyperoxaluria type 1

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "primary hyperoxaluria type 1" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-132588
CAS No.: 1834610-13-7
Synonyms: ALN-G01
Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-132613
CAS No.: 1834612-06-4
Purity:  99.21%
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
loading...
    loading...
Cat. No.: HY-148610
CAS No.: 893739-96-3
Target:  

Others

Research Areas:  

Metabolic Disease

LDH-IN-2, a salicylic acid derivative, is an inhibitor of glycolate oxidase (GO). LDH-IN-2 decreases oxalate output in hyperoxaluric hepatocytes. LDH-IN-2 can be used for research of primary hyperoxaluria type 1 (PH1) .
loading...
    loading...
Cat. No.: HY-W176012
CAS No.: 330977-65-6
Target:  

Others

Research Areas:  

Metabolic Disease

Glycolate oxidase-IN-1(compound 26), a salicylic acid derivative, is a glycolate oxidase (GO) inhibitor with an IC50 of 38.2 μM. Glycolate oxidase-IN-1 has the ability to reduce oxalate production in hyperoxalate hepatocytes and can be used in the study of primary hyperoxaluria type 1 (PH1) .
loading...
    loading...
Cat. No.: HY-180992
Target:  

Lactate Dehydrogenase

Research Areas:  

Metabolic Disease

Dual GO/LDHA-IN-1 is an orally available dual inhibitor targeting glycolate oxidase (GO) and lactate dehydrogenase A (LDHA), with Ki values of 390 nM and 40 nM, respectively. Dual GO/LDHA-IN-1 reduces hepatic LDHA levels, urinary oxalate excretion, and renal calcium-oxalate crystal deposition. Dual GO/LDHA-IN-1 is applicable for research on primary hyperoxaluria type 1 .
loading...
    loading...